These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 38734866)
1. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS). Young D; Harris C; Rahmany S; Iria I; Gonçalves J; Addison J; Harvey J; Latter S; Cummings F Int J Clin Pharm; 2024 Oct; 46(5):1091-1101. PubMed ID: 38734866 [TBL] [Abstract][Full Text] [Related]
2. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease. Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666 [TBL] [Abstract][Full Text] [Related]
3. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360 [TBL] [Abstract][Full Text] [Related]
6. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting. Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364 [TBL] [Abstract][Full Text] [Related]
8. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts. Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552 [TBL] [Abstract][Full Text] [Related]
9. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421 [TBL] [Abstract][Full Text] [Related]
10. SB5: An Adalimumab Biosimilar. Frampton JE BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234 [TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320 [TBL] [Abstract][Full Text] [Related]
13. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289 [TBL] [Abstract][Full Text] [Related]
14. The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5. Bouhnik Y; Carbonnel F; Fumery M; Flamant M; Buisson A; Camoin A; Addison J Dig Liver Dis; 2023 Dec; 55(12):1658-1666. PubMed ID: 37308394 [TBL] [Abstract][Full Text] [Related]
15. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature. Park D; Yun J; Hwang SJ; Park SJ Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330 [TBL] [Abstract][Full Text] [Related]
17. Patient perspectives of successful adalimumab biosimilar transitioning in Crohn's disease: an interview study. Young D; Cummings F; Latter S Eur J Hosp Pharm; 2022 Jul; 31(2):143-9. PubMed ID: 35853694 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302 [TBL] [Abstract][Full Text] [Related]
19. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe. Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522 [TBL] [Abstract][Full Text] [Related]
20. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. Shin D; Lee Y; Kim H; Körnicke T; Fuhr R J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]